Gel from Scientific Research

Western blotting of WT HT-29 ABE cells and cells harboring drug-resistance mutations activating the MAPK signaling pathway. Cells were treated with the combination of dabrafenib (80 nM) and cetuximab (1 µg ml −1 ) or DMSO as a control for 24 h before analysis.

DOI